Dynamin 2 (DNM2) is a large GTPase enzyme critical for membrane remodeling processes, including clathrin-mediated endocytosis, intracellular vesicle trafficking, and organelle division. As a member of the dynamin superfamily, it self-assembles into helical structures at membrane necks to mediate membrane fission through GTP-dependent conformational changes. DNM2 is ubiquitously expressed and interacts with multiple partners, such as endophilin and sorting nexins, to regulate cellular dynamics. Mutations in the *DNM2* gene are linked to human disorders like centronuclear myopathy (CNM) and Charcot-Marie-Tooth neuropathy (CMT), highlighting its physiological importance.
Dynamin 2 antibodies are essential tools for studying its expression, localization, and function. These antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to investigate DNM2’s role in cellular processes or disease mechanisms. For instance, researchers employ them to analyze DNM2 dysregulation in cancer metastasis, synaptic vesicle recycling in neurons, or abnormal membrane trafficking in genetic disorders. Monoclonal and polyclonal variants targeting specific domains (e.g., the GTPase or pleckstrin homology domains) help dissect structure-function relationships. Validation via knockout controls or siRNA knockdown ensures antibody specificity. Commercially available antibodies often include data on cross-reactivity and species compatibility, aiding experimental design. Reliable DNM2 antibodies are pivotal for advancing research in cell biology, neurobiology, and genetic disease therapeutics.